| scholarly article | Q13442814 |
| P50 | author | Henrik Zetterberg | Q6252048 |
| Kaj Blennow | Q28321550 | ||
| Oskar Hansson | Q30533735 | ||
| Gunnar Brinkmalm | Q42722971 | ||
| Kina Höglund | Q60977112 | ||
| Thomas G Beach | Q67218653 | ||
| Lucilla Parnetti | Q67469807 | ||
| Erik Portelius | Q76736817 | ||
| Tammaryn Lashley | Q85290690 | ||
| P2093 | author name string | Hsu-Hsin Chen | |
| Johan Gobom | |||
| Radu Constantinescu | |||
| Jessica Wahlgren | |||
| Claudia Cicognola | |||
| Nicholas C Cullen | |||
| Kristin Wildsmith | |||
| P2860 | cites work | Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 |
| Neuropathological stageing of Alzheimer-related changes | Q27860862 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
| Alzheimer's disease | Q30251865 | ||
| Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria | Q30458193 | ||
| Plasma Extracellular Vesicles Enriched for Neuronal Origin: A Potential Window into Brain Pathologic Processes. | Q33711915 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy | Q34633220 | ||
| Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease | Q35014708 | ||
| A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies | Q35206942 | ||
| Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. | Q35938561 | ||
| Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program | Q36121377 | ||
| Criteria for the diagnosis of corticobasal degeneration | Q36661843 | ||
| Expanding the cerebrospinal fluid endopeptidome | Q38775378 | ||
| CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis | Q38805517 | ||
| Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms | Q38874926 | ||
| Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias. | Q38992796 | ||
| AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons | Q39035671 | ||
| A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration. | Q39689304 | ||
| Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. | Q40131661 | ||
| Both total and phosphorylated tau are increased in Alzheimer's disease | Q41765446 | ||
| Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration | Q43509894 | ||
| CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder | Q44338777 | ||
| Role of N-terminal tau domain integrity on the survival of cerebellar granule neurons. | Q44654504 | ||
| Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. | Q45050796 | ||
| A peptide containing residues 26-44 of tau protein impairs mitochondrial oxidative phosphorylation acting at the level of the adenine nucleotide translocator. | Q46412685 | ||
| Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates | Q46488626 | ||
| Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization | Q49169032 | ||
| Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment | Q50537906 | ||
| Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. | Q50940972 | ||
| Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. | Q51723038 | ||
| Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS. | Q51930054 | ||
| Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 | ||
| A new rating scale for Alzheimer's disease. | Q53197509 | ||
| Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? | Q53212854 | ||
| Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 | ||
| Longitudinal stability evaluation of biomarkers and their correlation in cerebrospinal fluid and plasma from patients with Alzheimer's disease. | Q53332329 | ||
| Tau Kinetics in Neurons and the Human Central Nervous System | Q57215461 | ||
| SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders | Q60932476 | ||
| An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid | Q62128966 | ||
| Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy | Q73414107 | ||
| N-terminal fragments of tau inhibit full-length tau polymerization in vitro | Q79247556 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 279-296 | |
| P577 | publication date | 2018-12-13 | |
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. | |
| P478 | volume | 137 |
| Q93164263 | An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders |
| Q101135994 | Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes |
| Q95278387 | Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease |
| Q90644035 | Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer's disease |
| Q90464620 | Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase |
| Q96953378 | Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism |
| Q99585475 | Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer's disease models |
| Q89945308 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg |
| Q89860571 | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers |
| Q92480817 | Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans |
| Q92017939 | What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? |
Search more.